<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=551791532206281&amp;ev=PageView&amp;noscript=1">
Rapid Press Releases

    RapidAI Among the First Stroke Imaging Companies with Software Approved for Medicare New Technology Add-on Payment

    Stroke Imaging Makes Significant Stride in Reimbursement. Helps U.S. Hospitals More Easily Adopt the Latest Advancements in Stroke Care

    San Mateo, Calif. — October 1, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced Rapid LVO is among the first software products to qualify for the New Technology Add-on Payment (NTAP). NTAP is part of the CMS Inpatient Prospective Payment System (IPPS). A significant advancement in stroke care and reimbursement for Medicare patients, the news further fuels the expansion of advanced stroke imaging for those technologies that meet the NTAP requirements, foremost Rapid LVO from RapidAI.

    The new NTAP program applies to LVO triage and notification for stroke. Rapid LVO explicitly meets the definition of measuring arterial blood flow in the brain per the issued NTAP code definition. RapidAI offers the most comprehensive stroke imaging platform available. Once an LVO (Large Vessel Occlusion) is identified, Rapid ASPECTS can quantify the severity of the stroke, and Rapid CTP or Rapid MRI can then notify a stroke team if a patient is eligible for thrombectomy.

     “Our mission can be simply stated…save lives, save time and save money,” said Don Listwin, CEO of RapidAI. “This exciting new development in Medicare reimbursement may at first seem like just a bookkeeping issue or just a win for RapidAI, the industry leader. However, in truth, this is not a step forward for any one company, but instead an advancement for various software technologies with the end goals of saving more lives and enabling better patient outcomes.”

    RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging.

    To learn more visit www.RapidAI.com.

    Contact PR

    Peter Evers

    Natron Communications
    (415) 524-8899
    peter@natroncomm.com